133 related articles for article (PubMed ID: 7003455)
21. Inhibition of experimental colorectal cancer by razoxane (ICRF-159).
Gilbert JM; Thompson EM; Slavin G; Kark AE
Br J Surg; 1984 Aug; 71(8):600-3. PubMed ID: 6743979
[TBL] [Abstract][Full Text] [Related]
22. Phase I evaluation of ICRF-187 (NSC-169780) in patients with advanced malignancy.
Liesmann J; Belt R; Haas C; Hoogstraten B
Cancer; 1981 Apr; 47(8):1959-62. PubMed ID: 6784914
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
Rougier P; Bugat R; Douillard JY; Culine S; Suc E; Brunet P; Becouarn Y; Ychou M; Marty M; Extra JM; Bonneterre J; Adenis A; Seitz JF; Ganem G; Namer M; Conroy T; Negrier S; Merrouche Y; Burki F; Mousseau M; Herait P; Mahjoubi M
J Clin Oncol; 1997 Jan; 15(1):251-60. PubMed ID: 8996150
[TBL] [Abstract][Full Text] [Related]
24. High-dose continuous infusion folinic acid and bolus 5-fluorouracil in patients with advanced colorectal cancer: a phase II study.
Bertrand M; Doroshow JH; Multhauf P; Blayney DW; Carr BI; Cecchi G; Goldberg D; Leong L; Margolin K; Metter G
J Clin Oncol; 1986 Jul; 4(7):1058-61. PubMed ID: 3487626
[TBL] [Abstract][Full Text] [Related]
25. Phase II trial of combination chemotherapy of colonic cancer with 5-fluorouracil, mitomycin C, and hexamethylmelamine.
Bruckner HW; Storch JA; Brown JC; Goldberg J; Chamberlin K
Oncology; 1983; 40(3):161-4. PubMed ID: 6405337
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy of advanced colorectal carcinoma: fluorouracil alone vs. two drug combinations using fluorouracil, hydroxyurea, semustine, dacarbazine, razoxane, and mitomycin. A phase III trial by the Eastern Cooperative Oncology Group (EST: 1278).
Engstrom PF; MacIntyre JM; Mittelman A; Klaassen DJ
Am J Clin Oncol; 1984 Aug; 7(4):313-8. PubMed ID: 6377866
[TBL] [Abstract][Full Text] [Related]
27. [The combination methyl-CCNU, vincristine, 5-fluorouracil and streptozotocin in the treatment of advanced colo-rectal adenocarcinoma].
Togni P; Sessa C; Varini M; Cavalli F
Schweiz Med Wochenschr; 1982 Jun; 112(26):930-3. PubMed ID: 6214002
[TBL] [Abstract][Full Text] [Related]
28. Phase I-II evaluation of razoxane (ICRF-159) and doxorubicin in gastrointestinal cancer. A Southeastern Cancer Study Group Trial.
DeSimone PA; Greco FA; Omura GA; Bartolucci A
Am J Clin Oncol; 1986 Jun; 9(3):185-6. PubMed ID: 3728369
[TBL] [Abstract][Full Text] [Related]
29. Randomized clinical trial comparing two dose regimens of ICRF-159 in refractory malignant lymphomas.
O'Connell MJ; Begg CB; Silverstein MN; Glick JH; Oken MM
Cancer Treat Rep; 1980; 64(12):1355-8. PubMed ID: 7008938
[TBL] [Abstract][Full Text] [Related]
30. Combination chemotherapy (5-fluorouracil, methyl-CCNU, mitomycin C) versus 5-fluorouracil alone for advanced previously untreated colorectal carcinoma. A phase III study of the Piedmont Oncology Association.
Richards F; Case LD; White DR; Muss HB; Spurr CL; Jackson DV; Cooper MR; Zekan P; Cruz J; Stuart JJ
J Clin Oncol; 1986 Apr; 4(4):565-70. PubMed ID: 3514806
[TBL] [Abstract][Full Text] [Related]
31. Phase II trials of hexamethylmelamine, dianhydrogalactitol, razoxane, and beta-2'-deoxythioguanosine as single agents against advanced measurable tumors of the pancreas. Gastrointestinal Tumor Study Group.
Cancer Treat Rep; 1985 Jun; 69(6):713-6. PubMed ID: 3926311
[TBL] [Abstract][Full Text] [Related]
32. Baker's antifol in combination with 5-fluorouracil and methyl-CCNU in the treatment of metastatic colorectal cancer: a Southwest Oncology Group Study (Protocol 7764).
Shaw MT; Bonnet JD; Wilson H; Heilbrun LK
Cancer Treat Rep; 1980; 64(2-3):247-50. PubMed ID: 7407758
[TBL] [Abstract][Full Text] [Related]
33. Phase II trial of ICRF-187 in squamous cell carcinoma of the head and neck.
Wheeler RH; Bricker LJ; Natale RB; Baker SR
Cancer Treat Rep; 1984 Feb; 68(2):427-8. PubMed ID: 6421483
[TBL] [Abstract][Full Text] [Related]
34. Razoxane, metastasis and adjuvant chemotherapy.
Hellmann K
Clin Exp Metastasis; 1987; 5(1):1-2. PubMed ID: 3829493
[No Abstract] [Full Text] [Related]
35. Limited activity of ICRF-159 in advanced acute leukemia.
Bakowski MT; Prentice HG; Lister TA; Malpas JS; McElwain TJ; Powles RL
Cancer Treat Rep; 1979 Jan; 63(1):127-9. PubMed ID: 369684
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of ICRF-159 in refractory metastatic breast cancer.
Creech RH; Engstrom PF; Harris DT; Catalano RB; Bellet RE
Cancer Treat Rep; 1979 Jan; 63(1):111-4. PubMed ID: 369681
[TBL] [Abstract][Full Text] [Related]
37. Trials of adjuvant chemotherapy in colorectal cancer.
Gilbert JM
Drugs Exp Clin Res; 1986; 12(1-3):201-10. PubMed ID: 3525074
[TBL] [Abstract][Full Text] [Related]
38. Phase I trial of cisplatin and razoxane (ICRF-159) (NSC #119875) in advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Pilot Study.
Bonomi P; Yordan E; Blessing JA
Am J Clin Oncol; 1988 Feb; 11(1):1-2. PubMed ID: 3277372
[TBL] [Abstract][Full Text] [Related]
39. Phase I study of ICRF-187 using a daily for 3 days schedule.
Von Hoff DD; Howser D; Lewis BJ; Holcenberg J; Weiss RB; Young RC
Cancer Treat Rep; 1981; 65(3-4):249-52. PubMed ID: 6786738
[TBL] [Abstract][Full Text] [Related]
40. Pilot trial of prolonged continuous-infusion 5-fluorouracil and weekly cisplatin in advanced colorectal cancer.
Cantrell JE; Hart RD; Taylor RF; Harvey JH
Cancer Treat Rep; 1987 Jun; 71(6):615-8. PubMed ID: 3555789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
